GlassScriptPhysician profile
Nicole Brown
NPI 1558906750
$646.91
in general payments reported to CMS, 2019-2025
18 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $161 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $67.23 | 2025 | Rexulti |
| Novo Nordisk INC | $64.99 | 2025 | Ozempic, Rybelsus |
| Abiomed | $61.93 | 2024 | Impella |
| Lilly USA, LLC | $52.79 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $47.81 | 2024-2025 | Farxiga |
| Exact Sciences Corporation | $42.72 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.41 | 2025 | Caplyta |
| Medtronic, INC. | $40.27 | 2025 | Inceptiv |
| Abbvie INC. | $35.25 | 2025 | |
| Novartis Pharmaceuticals Corporation | $34.33 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $31.78 | 2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $30.44 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $20.79 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $17.19 | 2025 | Gemtesa |
| Dexcom, INC. | $15.94 | 2025 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.17 | 2025 | |
| Viatris Specialty LLC | $14.38 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $13.49 | 2025 | Bexsero, Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.